New Research Partnership With Horizon Therapeutics Could Be The Next Revenue Catalyst For Xeris

Xeris (NASDAQ:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Horizon Therapeutics (NASDAQ:HZNP).

Related Keywords

Warren Buffett ,Glen Santangelo ,Peter Warendort ,Ray Dalio ,Paul Edick ,Berkshire Hathaway ,Research Partnership With Horizon Therapeutics Could Be ,Horizon Therapeutics ,Full Ray Dalio Series ,Qualified Financial ,Thyroid Eye Disease ,